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Abstract
Background: The cost implication of variability in pancreatic surgery is not well described. It was
hypothesized that for a pancreaticoduodenectomy (PD), lower volume centres demonstrate worse peri-
operative outcomes at higher costs.
Methods: From 2009–2011, 9883 patients undergoing a PD were identified from the University
HealthSystems Consortium (UHC) database and stratified into quintiles by annual hospital case volume.
A decision analytic model was constructed to assess cost effectiveness. Total direct cost data were
based on Medicare cost/charge ratios and included readmission costs when applicable.
Results: The lowest volume centres demonstrated a higher peri-operative mortality rate (3.5% versus
1.3%, P < 0.001) compared with the highest volume centres. When both index and readmission costs
were considered, the per-patient total direct cost at the lowest volume centres was $23 005, or 10.9% (i.e.
$2263 per case) more than at the highest volume centres. One-way sensitivity analyses adjusting for
peri-operative mortality (1.3% at all centres) did not materially change the cost effectiveness analysis.
Differences in cost were largely recognized in the index admission; readmission costs were similar across
quintiles.
Conclusions: For PD, low volume centres have higher peri-operative mortality rates and 10.9% higher
cost per patient. Performance of PD at higher volume centres can lead to both better outcomes and
substantial cost savings.
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Introduction
Pancreatic malignancy, currently the 4th leading cause of cancer-
related death in the United States, is a complex disease process.1
From distinct screening and diagnostic challenges, to sophisti-
cated and complex surgical intervention, to the issue of marginally
effective chemotherapy and radiation therapy, the resources
devoted to treating this disease process are substantial. This reality,
unfortunately, is set in a context of increased health care utiliza-
tion restraints, with health care spending projected (and feared) to
become 25% of United States gross domestic product (GDP) by
the year 2025.2 In spite of current legislative efforts to curb this
unsustainable spending through the Affordable Care Act, there is
no question that health care providers will need to demonstrate
high-quality, lower cost care as our delivery system evolves.3
These constraints are clearly relevant to pancreatic cancer
surgery, as the high costs and substantial nihilism regarding this
disease process will only be amplified.4–7 To the credit of the pan-
creatic cancer surgical community and dedicated outcomes
researchers, there has already been substantial progress in dem-
onstrating which providers can deliver optimal patient care.8–14
Perhaps most convincingly, multiple investigators have shown
that high volume centres and surgeons are critical to minimizing
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peri-operative mortality, complications, and readmissions.8,9,11,12,14
Furthermore, variables such as National Cancer Institute
(NCI) designation, university affiliation, and patient-specific
factors are also critical in achieving the best clinical outcomes
possible.
In spite of these clear data regarding optimal patient-centre-
provider matching, complex pancreatic surgery continues to be
provided at low volume centres.15 This truth is a frustration that
reflects many individual components: patients’ inability (or
unwillingness) to travel, lack of a structured referral system, and
substantial financial incentives for providers to ‘hold on’ to
patients in spite of the recognition that their patients’ outcomes
may provemore optimal in a different system. That these obstacles
to optimal patient care continue to directly impact outcomes is
both unacceptable and an opportunity to improve care.
Although each of the aforementioned obstacles is significant,
and do not have simple answers, financial compensation is a com-
ponent of health care delivery that may be the single most impor-
tant driver by which to effect change. Specifically, reimbursing
providers and centres which perform well, and refusing to pay
poor-performing outliers, would quickly divert patients towards
high-functioning, lower cost centres. Not only would this
punitive/reward strategy save millions of dollars in cancer care,
but may also lead to better results for patients. To address this
issue, we investigated key peri-operative outcomes and their rela-
tionship to cost with the hypothesis that centres that perform
complex pancreatic surgery at a high volume demonstrate better
clinical outcomes at lower costs.
Methods
Patient selection and stratification
The University HealthSystems Consortium (UHC) is an alliance
of 120 academic medical centres and 299 of their affiliated hospi-
tals which compiles a database of previously validated
administrative-level institutional data.16 This dataset was queried
for all patients who underwent a pancreaticoduodenectomy
(PD) with the International Disease Classification version 9
(ICD-9) code 52.7 during the 3-year time period from 2009
through 2011. Patients with a Medicare-severity diagnosis-
related group (MS-DRG) coding of 405 (major complication[s]
and/or comorbidity/ies), 406 (minor complication[s] and/or
comorbidity/ies), or 407 (no complication or comorbidity)
throughout their index admission were identified and included in
further analysis. Using this cohort, the hospitals at which the
patients underwent surgery were stratified into quintiles (i.e.
lowest, low, middle, high and highest volume centres) based upon
the number of PD’s performed at each centre annually. Patient
data were then collated and further analysed as part of this volume
designated cohort. A cost effectiveness analysis was performed
utilizing the peri-operative mortality rate (defined as any post-
operative death prior to discharge from the index admission) and
the median patient-case total direct cost across volume quintiles.
The total direct cost, referred to as ‘cost’ throughout
the manuscript, reflects cost from a societal perspective (i.e.
reimbursement).
Decision analytic model
A decision analytic model (TreeAge Software,Williamstown, MA,
USA) was constructed to incorporate key clinical variables and
outcomes (Fig. 1). These included centre volume, peri-operative
mortality, patient-specific DRG, readmission status and cost data.
Specifically, cost included both index hospitalization and the first
readmission cost, when applicable. Cost was calculated by apply-
ing hospital-specific Medicare cost-to-charge ratios as reported to
Medicare (then reported to UHC), and incorporating region-
specific differences in wages and labour cost. Based on model
probability inputs and costs, results were reported in terms of cost
per index admission or readmission.
Deterministic sensitivity analyses were performed to test the
robustness of our conclusions by altering key clinical variables
within the model. Specifically, we varied peri-operative mortality
at each individual centre by applying the mortality rate at the
highest volume centre (i.e. 1.3%) to all centres. This rate was
chosen to test the model at the most extreme end of the observed
clinical results, and also to make results clinically meaningful in
terms of quality improvement; no quality improvement initiative
should aim to duplicate the results of the worst performing
hospitals.
Statistical analysis
Parametric variables were compared across quintiles with analysis
of variance (anova) whereas non-parametric variables were com-
pared across quintiles with Pearson’s chi-square tests. All statisti-
cal analyses were performed using SAS Statistical software 9.3
Figure 1 Decision analytic tree demonstrating elements of the cost-
effectiveness model constructed, including centre volume, peri-
operative mortality, patient-specific diagnosis-related group (DRG),
readmission rate and overall cost. A (DRG) code of 405 denotes a
patient with a major comorbidity or complication, 406 denotes a
patient with a minor comorbidity or complication, and 407 denotes
a patient without comorbidity or complication
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(SAS Institute Inc., Cary, NC, USA) and SigmaPlot software v11.0
(Systat Software, Inc., San Jose, CA, USA) with a P-value of <0.05
deemed significant.
Results
Hospital volume quintile stratification
A total of 9883 patients were identified within the UHC dataset
and included for further analysis. Patients were further stratified
according to the annual number of PD’s performed at each insti-
tution during the given year, yielding a cohort of approximately
2000 patients per volume cohort (Fig. 2). Stratifying by annual
case volume, a ‘lowest’ volume institution performed approxi-
mately 1–22 cases, a ‘low’ volume institution performed approxi-
mately 23–36 cases, a ‘middle’ volume institution performed
approximately 37–56 cases, a ‘high’ volume institution performed
approximately 57–90 cases and a ‘highest’ volume institution per-
formed greater than approximately 97 cases per year; slight vari-
ations in quintile cut-offs existed across years throughout the
study period. The median age of all patients was 65 years
[interquartile range (IQR) 53–69 years] with a roughly even male/
female distribution. Patient age and gender breakdown did not
differ significantly across volume quintiles.
Cost effectiveness analysis
The median total direct cost of a single patient undergoing a PD
across all quintiles was $21 775. Stratified by volume quintile, the
median total direct cost per patient varied across quintile: $23 005
per case for the lowest volume quintile, $21 588 per case for the
low volume quintile, $23 287 for the middle volume quintile,
$20 300 for the high volume quintile and $20 742 for the highest
volume quintile (Fig. 3a). Analysis of the total direct cost of each
patient’s care at the highest volume centres was approximately
10% less compared with the cost of care at the lowest volume
centres, a savings of approximately $2000 per patient-case
(P < 0.01).
Total direct cost data were further analysed in an attempt to
identify exactly where these cost discrepancies existed. First, strati-
fied by DRG code applied during the index admission, those
patients with DRG codes of 407 (i.e. patients without significant
comorbidities or post-operative complications) demonstrated
lower index admission costs than those patients with DRG codes
of 405 (major comorbidities and/or complications) or 406 (minor
comorbidities and/or complications); this discrepancy held true
across all quintiles (Table 1). Additionally, the lowest volume
centres consistently demonstrated higher costs per patient during
the index admission. When costs associated solely with readmis-
sion were analysed across quintiles, no significant differences
existed across DRG codes or across volume quintiles.
We next sought to determine whether a relationship existed
between hospital volume, peri-operative mortality and total direct
cost. For example, the two highest volume quintiles demonstrated
median costs of $20 300 to $20 742 per patient to achieve mortal-
ity rates of 1.3% to 1.5% (Fig. 3b). Comparatively, the two lowest
volume quintiles demonstrated median costs of $21 588 to
$23 005 to achieve mortality rates of 2.3 to 3.5%. The two highest
volume quintiles not only demonstrated improved peri-operative
mortality compared with lower volume centres, but they did so at
a substantial cost savings.
Sensitivity analysis
When applying the peri-operative mortality rate of the highest
volume centres (1.3%) to all centres, the median total direct costs
within each quintile did not significantly change as compared
with the base case (Table 2). Based on this model, even in the most
optimal scenario, if hospitals within the lowest volume quintile
were able to theoretically reduce their peri-operative mortality
rate from 3.5% to 1.3%, they would only reduce their base cost
from $23 005 to $22 501 per patient. In spite of this apparent
reduction in cost, institutions within the highest volume quintiles
still experience a cost savings of approximately $1800 per patient
to achieve the same post-operative outcome.
Discussion
In this study, we have demonstrated an association between
optimal short-term patient outcomes and the financial costs
associated with achieving those outcomes. Specifically, we
have shown that the centres performing the highest volume of
pancreaticoduodenectomies annually demonstrate the lowest
peri-operative mortality rates at lower costs to patients and to the
healthcare system.
A number of the findings in our study deserve special mention.
First, it should be recognized that the differences in cost are rooted
entirely in the index hospitalization – i.e. differences in total direct
cost across volume quintiles appear to be explained by the cost
Figure 2 Pancreaticoduodenectomy patients were identified from
the University HealthSystems Consortium clinical database and
resource manager and stratified into quintiles by the annual case
volume of the hospital at which he or she underwent resection. PD,
pancreaticoduodenectomy; UHC, University HealthSystems Con-
sortium; MS DRG, Medicare severity diagnosis-related group; MCC,
major comorbidity or complication; CC, minor comorbidity or
complication
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discrepancies within the index admissions themselves, rather than
discrepancies in costs associated with readmission. A significant
contributing factor to increased cost at the lowest volume centres
is the significantly increased duration of overall stay (11 versus 8
days, P < 0.01) as well as duration of care received within the
surgical intensive care unit (2 versus 1 days, P < 0.01) compared
with the highest volume hospitals. Although there was some vari-
ation in readmission costs based on initial hospital DRG, these
events were rare enough that they were not statistically significant.
This discovery enforces the notion that savings from readmission
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Figure 3 (a) The median total direct cost of each patient-case across volume quintiles. A significant volume–cost association was noted
across quintiles (P < 0.01). (b) The cost effectiveness plot demonstrates improved peri-operative mortality at lower costs at higher volume
institutions compared with lower volume institutions
Table 1 Total direct costs for index admission and readmission by DRG
Index admission cost by MS DRG Lowest Low Middle High Highest P
407
No readmission $16 930 $14 996 $16 771 $15 592 $15 041 0.05
Readmission $18 103 $15 964 $17 741 $15 575 $16 103 <0.001
406
No readmission $19 610 $17 292 $19 672 $16 901 $17 393 <0.001
Readmission $21 307 $19 007 $20 624 $17 430 $18 930 <0.001
405
No readmission $26 034 $22 133 $25 464 $21 208 $22 747 <0.001
Readmission $28 664 $26 239 $26 323 $25 678 $26 276 0.69
Death $45 119 $49 005 $52 528 $45 690 $37 808 0.60
Readmission Cost by index MS DRG
407 $5 554 $4 273 $5 052 $5 022 $5 402 0.48
406 $6 092 $5 453 $6 093 $5 072 $5 572 0.41
405 $5 711 $7 617 $6 620 $5 323 $7 389 0.18
MS DRG, Medicare severity diagnosis-related group; 407, MS DRG code applied to patient without comorbidity of complication; 406, MS DRG code
applied to patients with minor comorbidity or complication; 405, MS DRG code applied to patients with major comorbidity or complication.
Table 2 Sensitivity analysis
Volume quintile Base cost/
patient (US$)
Base cost if all centres
experienced the same
mortality rate of the highest
volume centre (1.3%)
Lowest volume $23 005 $22 501
Low volume $21 588 $21 307
Middle volume $23 387 $23 227
High volume $20 300 $20 248
Highest volume $20 742 $20 742
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are likely to be realized by reducing the absolute number of read-
missions rather than precisely where that patient goes for that
readmission and for what intervention(s). Second, these differ-
ences in cost between high and low volume centres were consistent
across all diagnosis-related group codes that populated our
model. This variability in index hospital total direct costs, skewed
significantly in favour of the highest volume centres, should
provide increased motivation and pressure to develop and stand-
ardize commonly accepted practice patterns that may minimize
excess resource utilization. Enhanced recovery after surgery pro-
grammes that include early enteral feeding, encourage early
ambulation and arrangement of home health care services are one
of several scenarios that could be implemented to hypothetically
minimize the use of excess hospital resources.
Furthermore, the analysis of cost compared with charge data
should be highlighted. Over 20 years ago, a research investigation
in the state of Maryland addressed a similar association between
economic and outcome issues studied herein.17 However, with
respect to finances, that research group utilized hospital charges
rather than costs. As we increasingly understand, there are signifi-
cant differences between ‘charges’ and ‘costs’ associated with sur-
gical procedures and subsequent hospitalizations. A hospital
system may effectively charge whatever its administrative
‘chargemaster’ dictates, without any reflection about what the
costs of services provided are or what the societal (i.e. payer) costs
truly are; as such, charges do not represent the most meaningful
financial data available to analyse the economic impact of a par-
ticular complex surgical operation. By incorporating total direct
costs rather than charges into our analysis, we are able to provide
a more reasonable and accurate estimate of resource utilization
from a societal perspective (at least in the Medicare population).
There are limitations to our study. UHC is an administrative
dataset in which, while reporting a multitude of clinical variables
with great accuracy, disease-specific complications are not reliably
reported. Similarly, the database currently lacks the ability to
perform risk-adjusted analyses on patient outcomes such as post-
operative complications and peri-operative mortality. Although
these data would be of interest, those analyses were not the focus
of this investigation. Our goal was to study broader scale out-
comes and cost metrics, and while complication data would be
valuable, they are only a component of the summary data that we
report here. Second, our cost data reflect Medicare payment,
which certainly does not apply to all patients and payers. Unfor-
tunately, all-payer data from either insurers or hospitals are
exceedingly difficult to ascertain, and the proprietary nature of
them do not lend themselves to routine publication. Third, as the
UHC database lacks such granular data as operative time,
radiographical imaging and specifics regarding interventional
procedures, it is difficult to ascertain which element(s) of the
index admission contribute most significantly to discrepancies in
cost effective care. The field of pancreatic surgery would benefit
from future studies designed to identify and investigate these
potential contributors to differences in cost. Lastly, as the UHC
database collects data primarily from tertiary care academic
centres and their affiliated hospitals, conclusions drawn from
these data may not always be accurately extrapolative to all hos-
pitals nationwide.
In spite of these limitations, we believe these data have signifi-
cant real-world implications. Convincing data about high volume
surgery and their superior outcomes have been known for over 20
years, yet lower volume, less-experienced providers continue to
perform pancreaticoduodenectomies. In reality, the only way such
practice patterns may change is if institutions that reliably report
sub-optimal outcomes are no longer reimbursed for these opera-
tions. To that end, based on our data demonstrating both better
outcomes and lower costs at higher volume centers, it may be
reasonable for insurers, both public and private, to limit reim-
bursements for complex hepato-pancreatico-biliary surgery for
hospitals consistently demonstrating outcomes below well-
established national benchmarks. While this may not be popular
throughout the health care community, it is a consideration that
may help improve the cost effectiveness of pancreatic cancer
surgery.
Conflicts of interest
None declared.
References
1. World Cancer Research Fund International. Pancreatic Cancer.
Available at: http://www.wcrf.org/cancer_statistics/data_specific_cancers/
pancreatic_cancer_statistics.php (last accessed 12 January 2014).
2. Munoz E, Munoz W 3rd, Wise L. (2010) National and surgical health care
expenditures, 2005–2025. Ann Surg 251:195–200.
3. Azvolinsky A. (2014) Academic medical centers fear squeeze from Afford-
able Care Act. Nat Med 20:106.
4. Short MN, Aloia TA, Ho V. (2014) The influence of complications on the
costs of complex cancer surgery. Cancer 120:1035–1041.
5. Bardou M, Le Ray I. (2013) Treatment of pancreatic cancer: a narrative
review of cost-effectiveness studies. Best Pract Res Clin Gastroenterol
27:881–892.
6. Cooper M, Newman NA, Ibrahim AM, Lam E, Herman JM, Singh VK et al.
(2013) Unnecessary tests and procedures in patients presenting with
solid tumors of the pancreas. J Gastrointest Surg 17:1218–1223.
7. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E et al.
(2011) Delivering affordable cancer care in high-income countries. Lancet
Oncol 12:933–980.
8. Birkmeyer JD, Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL,
Fisher ES. (1999) Effect of hospital volume on in-hospital mortality with
pancreaticoduodenectomy. Surgery 125:250–256.
9. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I
et al. (2002) Hospital volume and surgical mortality in the United States.
N Engl J Med 346:1128–1137.
10. Finlayson EV, Goodney PP, Birkmeyer JD. (2003) Hospital volume and
operative mortality in cancer surgery: a national study. Arch Surg
138:721–725; discussion 6.
11. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas
FL. (2003) Surgeon volume and operative mortality in the United States.
N Engl J Med 349:2117–2127.
1060 HPB
HPB 2014, 16, 1056–1061 © 2014 International Hepato-Pancreato-Biliary Association
12. Reames BN, Ghaferi AA, Birkmeyer JD, Dimick JB. (2013) Hospital
volume and operative mortality in the modern era. Ann Surg Dec 23
[Epub ahead of print].
13. Brennan MF. (2009) Quality pancreatic cancer care: it's still mostly about
volume. J Natl Cancer Inst 101:837–838.
14. Brennan MF, Radzyner M, Rubin DM. (2009) Outcome–more than just
operative mortality. J Surg Oncol 99:470–477.
15. Hayman AV, Fisher MJ, Kluz T, Merkow RP, Wang EC, Bentrem DJ.
(2013) Is Illinois heeding the call to regionalize pancreatic surgery? J Surg
Oncol 107:685–691.
16. University HealthSystems Consortium. About UHC. Available at: https://
www.uhc.edu/12443.htm (last accessed 12 January 2014).
17. Sosa JA, Bowman HM, Gordon TA, Bass EB, Yeo CJ, Lillemoe KD et al.
(1998) Importance of hospital volume in the overall management of pan-
creatic cancer. Ann Surg 228:429–438.
HPB 1061
HPB 2014, 16, 1056–1061 © 2014 International Hepato-Pancreato-Biliary Association
